news
South Africa wants to make its own HIV prevention jab
South Africa is looking to locally produce lenacapavir, a six-monthly injectable for HIV prevention, despite cheaper generics from other countries expected by 2027. The move prioritizes quick access to the drug and building domestic manufacturing skills. It’s a bet on national health capacity over immediate cost savings.
South Africa is looking to locally produce lenacapavir, a six-monthly injectable for HIV prevention, despite cheaper generics from other countries expected by 2027. The move prioritizes quick access to the drug and building domestic manufacturing skills. It’s a bet on national health capacity over immediate cost savings.
The architecture take
South Africa's plan to make its own HIV prevention injection, lenacapavir, is less about immediate savings and more about long-term control over its population's health. You'd think cheaper generics would win, but this isn't just a pricing game; it's about supply chain resilience and national sovereignty. Imagine a world where a country's health isn't dictated by international shipping lanes or the whims of a few big pharma companies. That's the play here. Building local manufacturing capacity means they can scale production faster in a crisis, ensure consistent supply, and potentially adapt formulations down the road. It’s a strategic investment in public health, protecting millions of immune systems, not just a pharmaceutical purchase. My bet is more countries will follow this self-reliance model, especially for critical health interventions. Cost now, capacity later.